PHIO | tickerfilter.com

Fundamental analysis

13%

Profitability 8%

Dept financing 6%

Liquidity 50%

Performance 10%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.10%

1 Month

-26.52%

3 Months

-53.17%

6 Months

-59.82%

1 Year

41.28%

2 Year

-75.77%

Key data

Stock price

$1.33

P/E Ratio

0.00

DAY RANGE

$1.32 - $1.44

EPS

-$14.75

52 WEEK RANGE

$0.57 - $9.79

52 WEEK CHANGE

$40.15

MARKET CAP

2.969 M

YIELD

N/A

SHARES OUTSTANDING

860.721 K

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

3.85

PUBLIC FLOAT

AVERAGE 10 VOLUME

$144,731

AVERAGE 30 VOLUME

$160,152

Company detail

CEO: Geert C. PhD
Region: US
Website: phiopharma.com
Employees: 10
IPO year: 2010

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. Company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT) PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression.

PHIO - Phio Pharmaceuticals Corp.